Regeneron Pharmaceuticals, Inc.
Explore Regeneron Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Acquisitions
3
Total Acquisitions
$364M
Disclosed Deal Value
2024
$5M
Create Regeneron Cell Medicines and bring cell-therapy programs in-house.
Added personnel, infrastructure, and preclinical/clinical cell-therapy assets.
Broadened Regeneron's research modalities beyond antibodies.
2023
$109M
Expand genetic-medicine and hearing-loss programs.
Added DB-OTO and preclinical hearing-loss gene-therapy programs.
DB-OTO remains investigational in Phase 1/2 CHORD; no approval claim is made.
2022
$250M
Add investigational innate immune activation work for oncology combinations.
Added vidutolimod and TLR9 agonist expertise.
Strategic oncology pipeline expansion.
Regeneron's growth strategy centers on defending ophthalmology, scaling Dupixent economics, expanding Libtayo and oncology combinations, and selectively acquiring or partnering for new modalities.
Regeneron makes money from direct product sales and collaboration revenue. U.S. EYLEA and EYLEA HD sales, global Libtayo sales, rare-disease medicines, Sanofi profit-share economics for Dupixent, and Bayer EYLEA collaboration revenue are the main pillars.
Important deals include Checkmate Pharmaceuticals, Decibel Therapeutics, and the 2seventy bio cell-therapy platform transaction.
The deals add modalities outside Regeneron's original antibody base, including immuno-oncology, gene therapy, and cell therapy.
No. Regeneron still depends heavily on internal discovery and partnerships; acquisitions are targeted additions rather than the whole growth model.
Investors should watch whether acquired platforms produce approved medicines and whether Regeneron avoids overstating early-stage clinical assets.